Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.01.30
The relationship between liver disease and sarcopenia
Today, we would like to introduce the interaction between the liver and the muscular system. The liver has been known to work closely with other organs and in fact, in previous emails, we have mentioned some of the interactions between the liver and gut. However, today we would like focus on how the liver…
2025.01.30
The STAM mouse model: a clinically relevant, spontaneous HCC model
Today, we would like to introduce a study published by our client using our STAMTM mouse model (Dow, et al. Proc Natl Acad Sci U S A. 2018). The STAMTM model is a pathological model, with a NASH background, that spontaneously develops hepatocellular carcinoma (HCC). In this paper, the author compared the transcriptomes taken…
2025.01.30
Effect of the gut-liver axis dysfunction in liver disease
Today, We would like to introduce the relationship between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and the gut. MASLD is a disease that progresses from fatty liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH) to liver fibrosis and finally to liver cancer. As various factors such as diet and metabolic abnormalities are involved in the progression…
2025.01.30
Drug Efficacy Studies in NASH Mouse Model_ Mesenchymal stem/stromal cell small extracellular vesicles
Today’s topic is Effective cell therapy and exosome for NASH treatment. I would like to introduce a study published by our client, Agency for Science, Technology and Research (A*STAR) (SGP), in which they used our pre-clinical services in our proprietary NASH model called STAM™. Title: MSC-sEV Treatment Polarizes Pro-Fibrotic M2 Macrophages without Exacerbating Liver…
2025.01.30
Preventing Liver Cancer by Improving the Intestinal Dysbiosis
Today, we would like to introduce a study case of drug efficacy evaluation study using our mouse model of liver cancer caused by chronic liver disease (MASH/NASH). In this studies using our liver cancer model mice, it was found that not only the liver but also the intestines are important target organs in the treatment…
2025.01.30
Gut Microbiome As a Target For NASH Therapeutics Study
We introduce the development of drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) focusing on the gut microbiome and overview of studies using our STAMTM mice. Currently, the development of treatment and prevention methods for various diseases targeting the gut microbiome is progressing around the world. The relationship between MASH and the gut microbiome, such as…
2025.01.30
Drug efficacy study in NASH mouse model
Today we would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) model (Murakami et al., Cells., 2022). In this paper, the authors evaluated the effect of pemafibrate, a selective PPARa modulator, and tofogliflozin, an inhibitor of Na+/glucose-conjugated transport carrier 2, alone and in combination on the progression of…
2025.01.30
Introduction of the paper using NASH model mouse
One of our clients, Kagawa University, has published the results of a study using our non-alcoholic steatohepatitis (NASH) model on the PLOS ONE Journal. The authors demonstrated that ipragliflozin, an oral selective SGLT2 inhibitor, had a therapeutic effect on the NASH mouse model. Ipragliflozin attenuated the development of steatosis, ballooning, inflammation as well as liver…
2025.01.30
Drug Efficacy Studies in NASH Mouse Model_TGF-b neutralizing antibody
Today, we would like to introduce a study published by our client using our STAM™ mouse model (Okrah et al., npj Precision Oncology, 2018). Title: “Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology” KEYWORD: NASH, HCC, TGF-β, T cells In case you are unfamiliar with…
2025.01.30
Clinically correlated adipose tissue in liver disease model
MASH (Metabolic Dysfunction-Associated Steatohepatitis) is the progressive form of MASLD. The multiple parallel hits hypothesis has been recognized as the pathophysiology underlying MASH/NASH, namely, multiple factors such as alterations in adipose tissue and gut microbial functions contribute to the onset and progression of MASH/NASH [Tilg et al, 2021]. The adipose tissue is also…
We can help you advance your research.